Orion Oyj

Orion Oyj is a globally operating Finnish pharmaceutical company dedicated to developing, manufacturing, and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs). Headquartered in Espoo, Finland, the company's mission revolves around "building well-being" by empowering individuals to live their lives to the fullest.

The company's extensive product portfolio includes proprietary drugs, generic medicines, self-care products such as non-prescription medicines, vitamins, and skincare items, as well as veterinary pharmaceuticals. Orion's research and development efforts primarily focus on central nervous system (CNS) disorders, oncology, and respiratory diseases. Key proprietary products include Nubeqa for prostate cancer, dexdor/Precedex for intensive care sedation, Stalevo/Comtess/Comtan for Parkinson's disease, Simdax for acute decompensated heart failure, and the Easyhaler dry powder inhaler series for asthma and COPD. Orion serves a diverse customer base, including specialists, general practitioners, veterinarians, pharmacies, hospitals, and laboratories, with a strong market presence in Finland and operations across other European countries, North America, and internationally.

Led by President and CEO Liisa Hurme, Orion Oyj is publicly traded on Nasdaq Helsinki with tickers ORNAV and ORNBV. In recent news, the company reported significant growth in net sales and operating profit for Q1 2026. Orion Pharma also initiated a Phase 1b/2 basket trial for its investigational compound ODM-212 in advanced solid tumors and received Orphan Drug Designation for ODM-212 in mesothelioma from the US FDA in April 2026. The company continues to strategically position itself for growth, aiming for EUR 1.5 billion in net sales by the end of 2025.